Want to see FEMY full AI Analyst Report?
FEMY Stock Chart & Stats
$3.71
-$0.08(-2.11%)
At close: 4:00 PM EDT
$3.71
-$0.08(-2.11%)
Day’s Range― - ―
52-Week Range$2.64 - $22.22
Previous Close$3.71
Volume35.27K
Average Volume (3M)47.64K
Market Cap
$8.64M
Enterprise Value$32.16
Total Cash (Recent Filing)$5.39M
Total Debt (Recent Filing)$4.73M
Price to Earnings (P/E)―
Beta0.88
Next Earnings
Aug 12, 2026EPS Estimate
-1.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.43
Shares Outstanding3,019,534
10 Day Avg. Volume57,656
30 Day Avg. Volume47,638
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)3.88
Price to Sales (P/S)9.93
P/FCF Ratio-1.19
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$30.00Price Target Upside708.63% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-4.33
Revenue Forecast (FY)$3.77M
Bulls Say, Bears Say
Bulls Say
Improving Revenue TrajectorySustained revenue growth over multiple years indicates genuine commercial traction for FemVue/FemCath products in OBGYN and fertility practices. That expanding procedure base and adoption of consumables create a durable runway for scale, improving leverage on fixed costs as volumes rise.
Healthy Gross Margins On Device SalesHigh gross margins are characteristic of single-use medtech devices and suggest attractive unit economics once fixed overhead is absorbed. Sustained ~50–67% margins provide structural profitability potential as revenue scales, supporting long-term margin recovery if operating expenses normalize.
Scalable U.S. Manufacturing & Experienced LeadershipHaving scalable domestic manufacturing capacity and seasoned management supports reliable supply, faster product launches and global regulatory navigation. These capabilities underpin sustainable commercialization of existing products and new launches (e.g., FemaSeed/FemBloc), aiding durable market expansion.
Bears Say
Large Recurring Cash BurnPersistent, sizable negative operating and free cash flow relative to a sub-$3M revenue base indicates the business cannot self-fund near-term operations. That structural cash burn requires ongoing external capital, raising dilution risk and constraining long-term investments in sales, R&D and commercialization.
Extremely Negative Operating And Net MarginsVery large operating and net losses show fixed and operating cost structure far outpaces current revenue. This persistent unprofitability undermines returns and indicates the business is not yet scalable; sustained margin deficits will pressure balance sheet and require meaningful revenue expansion or cost reduction.
Reliance On External Capital Despite Improved LeverageAlthough leverage metrics improved and equity rose, the company remains dependent on outside funding to cover ongoing losses. That structural funding reliance creates execution risk, potential dilution, and a constrained ability to pursue longer-term commercial initiatives without favorable financing access.
Femasys News
FEMY FAQ
What was Femasys’s price range in the past 12 months?
Femasys lowest stock price was $2.64 and its highest was $22.22 in the past 12 months.
What is Femasys’s market cap?
Femasys’s market cap is $8.64M.
When is Femasys’s upcoming earnings report date?
Femasys’s upcoming earnings report date is Aug 12, 2026 which is in 6 days.
How were Femasys’s earnings last quarter?
Currently, no data Available
Is Femasys overvalued?
According to Wall Street analysts Femasys’s price is currently Undervalued.
Does Femasys pay dividends?
Femasys does not currently pay dividends.
What is Femasys’s EPS estimate?
Femasys’s EPS estimate is -1.27.
How many shares outstanding does Femasys have?
Femasys has 3,019,534 shares outstanding.
What happened to Femasys’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Femasys?
Currently, no hedge funds are holding shares in FEMY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Femasys
Femasys Inc., a biomedical company established in 2004 and based in Suwanee, Georgia, primarily targets the women's healthcare market within the United States. The firm's innovative product line includes permanent contraceptive solutions such as FemBloc and FemChec, alongside FemaSeed, which is an artificial insemination offering. For diagnostic purposes, Femasys provides FemCerv, a biopsy device utilized for endocervical curettage, and FemEMB, a product candidate intended for endometrial sampling to assist in the detection of uterine cancer. Additionally, the company markets its FemVue saline-air device across various international regions, including the U.S., Europe, Canada, and Japan. Its infertility-related products are supplied to obstetrician-gynecologists, other allied healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. The company also offers a range of non-surgical product technologies.
FEMY Stock 12 Month Forecast
Average Price Target
$30.00
▲(708.63% Upside)
Technical Analysis
Retractable Technologies
―
Milestone Scientific
―
Precision Optics Corporation
―
NexGel Inc
―
―
Ownership Overview
16.27% Insiders
52.41% Mutual Funds
― Other Institutional Investors
29.26% Public Companies and
Individual Investors